Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that from 2005 to 2017 developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017.

Until 05 February 2024, the ADR of Forward Pharma A/S was trading with restrictions over-the-counter (OTC) and more information can be found at:

On 08 January 2024, Forward Pharma announced that the ADR facility would be terminated effective at 5:00 PM (Eastern Time) on February 5, 2024.

Kindly see additional information at the website of the Depositary Bank of New York Mellon (